From: Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients
 | Objective | Group A+B | Group C |
---|---|---|---|
 |  | Spinal Cord | |
D1% [Gy] | 46Gy | 37.7 ± 6.8 [max 44.2] | 22.5 ± 19.8 [max 39.7] |
 |  | Brain Stem | |
D1% [Gy] | 54Gy | 25.5 ± 13.0 [max 49.4] | 30.2 ± 12.4 [max 48.7] |
 |  | Parotid | |
Volume [cm3] |  | 21 ± 7 | 24 ± 9 |
Mean [Gy] | < 26Gy | 21.5 ± 6.4 [max 38.2] | 14.7 ± 10.2 [max 25.9] |
V30Gy [%] | < 45% | 24.4 ± 13.7 [max 64.6] | 10.5 ± 11.8 [max 26.7] |
 |  | Parotid-PTV | |
Volume [cm3] |  | 20 ± 7 | 24 ± 10 |
Mean [Gy] | < 26Gy | 19.7 ± 5.6 [max 36.4] | 13.8 ± 9.3 [max 25.0] |
V30Gy [%] | < 45% | 20.4 ± 11.9 [max 61.9] | 8.0 ± 8.6 [max 16.8] |
 |  | Oral Cavity | |
Mean [Gy] |  | 28.3 ± 9.8 [max 40.8] |  |
V40Gy [%] | < 50% | 20.0 ± 15.7 [max 43.2] |  |
 |  | Larynx | |
Mean [Gy] |  | 34.9 ± 6.4 [max 44.3] |  |
V40Gy [%] | < 50% | 26.6 ± 14.6 [max 42.8] |  |
 |  | Eyes | |
Mean [Gy] |  |  | 23.5 ± 8.8 [max 43.6] |
V40Gy [%] | < 50% |  | 10.1 ± 17.5 [max 57.1] |
 |  | Optic Nerves | |
D1% [Gy] | < 50Gy |  | 46.7 ± 6.8 [max 56.3] |
 |  | Chiasm | |
D1% [Gy] | < 50Gy |  | 40.7 ± 9.0 [max 47.4] |
 |  | Healthy tissue | |
Volume [dm3] |  | 12.57 ± 4.56 | 11.40 ± 6.42 |
Mean [Gy] |  | 6.4 ± 2.9 | 4.4 ± 2.2 |
V5Gy [dm3] |  | 3.21 ± 1.42 | 2.36 ± 1.18 |
V10Gy [dm3] |  | 2.45 ± 1.12 | 1.73 ± 1.00 |
EI100% |  | 0.53 ± 1.26 | 0.80 ± 0.90 |
DoseInt [Gy dm3] |  | 72.87 ± 25.23 | 42.78 ± 26.02 |